4887 related articles for article (PubMed ID: 3264344)
1. Fractionated extract of Astragalus membranaceus, a Chinese medicinal herb, potentiates LAK cell cytotoxicity generated by a low dose of recombinant interleukin-2.
Chu DT; Lepe-Zuniga J; Wong WL; LaPushin R; Mavligit GM
J Clin Lab Immunol; 1988 Aug; 26(4):183-7. PubMed ID: 3264344
[TBL] [Abstract][Full Text] [Related]
2. [F3, a fractionated extract of Astragalus membranaceus, potentiates lymphokine-activated killer cell cytotoxicity generated by low-dose recombinant interleukin-2].
Chu D; Sun Y; Lin J; Wong W; Mavligit G
Zhong Xi Yi Jie He Za Zhi; 1990 Jan; 10(1):34-6, 5. PubMed ID: 2350835
[TBL] [Abstract][Full Text] [Related]
3. Phytochemicals potentiate interleukin-2 generated lymphokine-activated killer cell cytotoxicity against murine renal cell carcinoma.
Wang Y; Qian XJ; Hadley HR; Lau BH
Mol Biother; 1992 Sep; 4(3):143-6. PubMed ID: 1445669
[TBL] [Abstract][Full Text] [Related]
4. [The in vitro potentiation of LAK cell cytotoxicity in cancer and aids patients induced by F3--a fractionated extract of Astragalus membranaceus].
Chu DT; Lin JR; Wong W
Zhonghua Zhong Liu Za Zhi; 1994 May; 16(3):167-71. PubMed ID: 7956691
[TBL] [Abstract][Full Text] [Related]
5. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
6. Transforming growth factor-beta 1 (TGF-beta 1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-beta 1 and TGF-beta 2, and recombinant human TGF-beta 1.
Espevik T; Figari IS; Ranges GE; Palladino MA
J Immunol; 1988 Apr; 140(7):2312-6. PubMed ID: 3280680
[TBL] [Abstract][Full Text] [Related]
7. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy with Chinese medicinal herbs. II. Reversal of cyclophosphamide-induced immune suppression by administration of fractionated Astragalus membranaceus in vivo.
Chu DT; Wong WL; Mavligit GM
J Clin Lab Immunol; 1988 Mar; 25(3):125-9. PubMed ID: 3260961
[TBL] [Abstract][Full Text] [Related]
9. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-2 antitumor and effector cell responses.
Hawkins MJ
Semin Oncol; 1993 Dec; 20(6 Suppl 9):52-9. PubMed ID: 8284693
[TBL] [Abstract][Full Text] [Related]
11. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
Lafreniere R; Rosenberg SA
J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
[TBL] [Abstract][Full Text] [Related]
12. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
[TBL] [Abstract][Full Text] [Related]
13. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
Lafreniere R; Rosenberg SA
Cancer Res; 1985 Aug; 45(8):3735-41. PubMed ID: 3893689
[TBL] [Abstract][Full Text] [Related]
14. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
Shiloni E; Eisenthal A; Sachs D; Rosenberg SA
J Immunol; 1987 Mar; 138(6):1992-8. PubMed ID: 3493293
[TBL] [Abstract][Full Text] [Related]
15. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy with Chinese medicinal herbs. I. Immune restoration of local xenogeneic graft-versus-host reaction in cancer patients by fractionated Astragalus membranaceus in vitro.
Chu DT; Wong WL; Mavligit GM
J Clin Lab Immunol; 1988 Mar; 25(3):119-23. PubMed ID: 3260960
[TBL] [Abstract][Full Text] [Related]
17. Protective effect of extract from Paeonia lactiflora and Astragalus membranaceus against liver injury induced by bacillus Calmette-Guérin and lipopolysaccharide in mice.
Sun WY; Wei W; Gui SY; Wu L; Wang H
Basic Clin Pharmacol Toxicol; 2008 Aug; 103(2):143-9. PubMed ID: 18816297
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2.
Rosenberg SA; Mulé JJ
Surgery; 1985 Sep; 98(3):437-44. PubMed ID: 3898451
[TBL] [Abstract][Full Text] [Related]
19. In vitro generation of immune effector cells from tumor-associated lymphocytes of human gastric cancer.
Kim HJ; Heo DS; Suh CI; Kim HT; Bang YJ; Kim NK
Anticancer Res; 1995; 15(4):1247-55. PubMed ID: 7654004
[TBL] [Abstract][Full Text] [Related]
20. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.
Mulé JJ; Shu S; Rosenberg SA
J Immunol; 1985 Jul; 135(1):646-52. PubMed ID: 3889158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
